Catalin Rusnac
Deals and Financings
Shanghai’s HutchMed (HCM; HK: 13) out-licensed global rights (ex-China) for a colorectal cancer therapy to Japan’s Takeda (TAK; TSE: 4502) in a deal worth up to $1.13 billion, including $400 million upfront (see story). Fruquintinib, an oral drug, inhibits VEGFR-1-2 and 3. In China, the drug has been approved for use in CRC since 2018, and HutchMed is currently filing for US and EU approval. HutchMed believes fruquintinib has the potential to be used in subtypes of refractory metastatic colorectal cancer, regardless of biomarker status. In addition to the $1.13 billion, HutchMed will also pay royalties on net sales.
HBM Alpha Therapeutics (HBMAT), a novel endocrine disease biotech incubated by Harbour BioMed (HK: 02142) of the US and China, completed a seed financing to advance its two leading candidates. The company is developing novel antibody therapies for congenital adrenal hyperplasia and polycystic ovary syndrome, with the lead candidate currently in IND-enabling stage. HBMAT, headquartered in Cambridge, MA is a JV formed by HBM and Boston Children’s Hospital, an affiliate of Harvard Medical School, which owned the original rights to the two candidates. The financing will be used to advance the molecules into clinical trials.
Trials and Approvals
Guangzhou Akeso (OTCPK:AKESF; HK: 9926) was approved to market penpulimab, an anti PD-1 mAb, as a first-line treatment in China for squamous non-small cell lung cancer (see story). Akeso co-developed the drug with Sino Biopharma (OTCPK:SBMFF, OTCPK:SBHMY; HK: 1177). In August, 2021, the drug was approved as a third-line therapy to treat classic Hodgkin’s lymphoma. Last month, Akeso out-licensed ex-China rights for its bispecific PD-1/VEGF candidate to California’s Summit Therapeutics (SMMT) in a deal worth up to $5 billion ($500 million upfront). Akeso develops first-in-class and best-in-class medicines for global markets.
Legend Biotech (LEGN), a New Jersey-Nanjing biotech, announced its CAR-T therapy improved progression-free survival compared to standard therapies in patients with relapsed-refractory multiple myeloma. The results came from a global Phase III trial that enrolled patients with as few as one prior round of therapy. The company did not release specific data from the trial. One year ago, the candidate, Carvykti (cilta-cel), was approved in the US and EU as a fifth-line therapy for R/R MM. In late 2017, Janssen paid $350 million upfront to partner the drug with Legend.
Shanghai Junshi Biosciences’ (OTCPK:SHJBF; HK: 1877; SHA: 688180) NDA for a COVID-19 treatment has been accepted for review by China’s NMPA (see story). The Deuremidevir Hydrobromide Tablet, known as VV11, is an oral nucleoside analog anti-SARS-CoV-2 drug that inhibits the replication of SARS-CoV-2. In a Phase III trial, it lowered recovery time compared to Pfizer’s (PFE) Paxlovid, the current standard of care. VV116 was developed by a network of China government institutes, including the Shanghai Institute of Materia Medica, plus Suzhou Vigonvita Life Sciences and Junshi Bio.
Hangzhou Ascletis (OTCPK:ASCLF; HK: 1672) reported China approved its IND for ASC10, an oral treatment for monkeypox. The company described ASC10 as a double prodrug consisting of ASC10 and the single prodrug molnupiravir, a COVID therapy, which are converted in vivo into the same active metabolite ASC10-A. In preclinical studies, ASC10-A has shown broad spectrum antiviral activity against monkeypox and SARS-CoV-2 viruses. Ascletis has completed a Phase I safety trial in China for ASC-10 as a therapy for COVID. Monkeypox is an orthopoxvirus that causes symptoms similar to smallpox.
Disclosure: None.
Editor’s Note: The summary bullets for this article were chosen by Seeking Alpha editors.
Editor’s Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
Be the first to comment